Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Deferred Tax (2022 - 2023)

Syndax Pharmaceuticals (SNDX) has 2 years of Long-Term Deferred Tax data on record, last reported at $53.7 million in Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax rose 9.82% year-over-year to $53.7 million; the TTM value through Dec 2023 reached $53.7 million, up 9.82%, while the annual FY2023 figure was $53.7 million, 9.82% up from the prior year.
  • Long-Term Deferred Tax reached $53.7 million in Q4 2023 per SNDX's latest filing, up from $48.9 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $53.7 million in Q4 2023 and bottomed at $48.9 million in Q4 2022.